Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership lessened its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 9.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,216,373 shares of the company's stock after selling 419,019 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 0.13% of Takeda Pharmaceutical worth $55,825,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in TAK. Orion Portfolio Solutions LLC purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter worth approximately $172,000. Blair William & Co. IL boosted its stake in Takeda Pharmaceutical by 8.1% during the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock worth $162,000 after purchasing an additional 913 shares during the period. JPMorgan Chase & Co. grew its position in Takeda Pharmaceutical by 94.5% during the 4th quarter. JPMorgan Chase & Co. now owns 83,826 shares of the company's stock worth $1,110,000 after purchasing an additional 40,721 shares during the last quarter. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical in the fourth quarter valued at $52,000. Finally, LPL Financial LLC raised its holdings in shares of Takeda Pharmaceutical by 1.9% in the fourth quarter. LPL Financial LLC now owns 186,652 shares of the company's stock valued at $2,471,000 after buying an additional 3,564 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Analysts Set New Price Targets

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday.

Remove Ads

Takeda Pharmaceutical Stock Performance

Shares of TAK stock traded down $0.45 during midday trading on Friday, hitting $14.74. The company had a trading volume of 4,265,493 shares, compared to its average volume of 1,817,418. The stock has a market cap of $46.89 billion, a price-to-earnings ratio of 36.84, a PEG ratio of 0.24 and a beta of 0.39. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The company's 50 day simple moving average is $14.35 and its 200 day simple moving average is $13.92. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.37.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.